Skip to content

Mesterolone

Overview

Medical Information

Dosage Information

Side Effects

Safety Information

Reference Information

Frequently Asked Questions

What is the recommended dosage for Mesterolone?

Adults: Initial dose is 75-150 mg daily in divided doses for several months; maintenance dose is 50-75 mg daily. Not for use in children.

What are the primary uses of Mesterolone?

Treatment of male hypogonadism and male infertility associated with androgen deficiency.

What are the common side effects of Mesterolone?

Acne, increased libido, mood swings, hair loss, increased body hair growth, frequent or prolonged erections.

What are the serious side effects of Mesterolone?

Liver abnormalities (including tumors), jaundice, priapism, allergic reactions.

Is Mesterolone safe to use in patients with liver disease?

No, mesterolone is contraindicated in patients with existing or prior liver tumors. Use with caution in patients with other liver conditions and monitor liver function.

Can Mesterolone be used in women?

No, mesterolone is contraindicated in women due to the risk of virilization.

Does Mesterolone interact with other medications?

Yes, mesterolone can interact with anticoagulants, antidiabetics, and other anabolic steroids. It may also interact with medications metabolized by the liver. A full medication review is essential before prescribing.

Is Mesterolone safe to use during pregnancy or breastfeeding?

No, Mesterolone is contraindicated in pregnancy and breastfeeding.

How does Mesterolone affect fertility?

Mesterolone can improve sperm count and quality in some men with hypogonadism-related infertility, but it can also inhibit spermatogenesis at higher doses.

Can Mesterolone be used to enhance muscle growth in healthy individuals?

No, Mesterolone is not indicated for enhancing muscular development or physical ability in healthy individuals. Its anabolic effects are weak, and the risks outweigh the potential benefits in this context. *Please note that this information is current as of February 16, 2025, and may be subject to change with further research and clinical experience.